Pre-exposure prophylaxis in the EU/EEA setting: challenges and opportunities

Event
27 Apr 2016 - 28 Apr 2016
Stockholm, Sweden
ECDC

Although clinical trials and other studies have demonstrated the efficacy and effectiveness of pre-exposure prophylaxis (PrEP) for HIV and existing guidelines have recommended making PrEP available within combination HIV prevention packages, there is not yet clear consensus in Europe with regard to whether and how to implement PrEP.

Although clinical trials and other studies have demonstrated the efficacy and effectiveness of pre-exposure prophylaxis (PrEP) for HIV and existing guidelines have recommended making PrEP available within combination HIV prevention packages, there is not yet clear consensus in Europe with regard to whether and how to implement PrEP.

At this meeting, invited experts discussed pending issues related to service models of PrEP implementation in the EU/EEA Member States. Topics included appropriate models of care/services, cost-effectiveness, eligibility criteria, drug resistance, routine monitoring of people on PrEP, including adherence to treatment and regular testing for HIV and other sexually transmitted infections.
 
In the final session, participants were asked to identify priority issues emerging from the meeting and to suggest possible areas where ECDC might provide support to EU/EEA Member States.
 
A report of the meeting is available on request. Please email STIHIVHEP@ecdc.europa.eu if you wish to get a copy.
 Related link:Read a summary of the meeting in EurosurveillanceHIV/AIDS surveillance in Europe 2014